Axsome Therapeutics Inc (AXSM)vsMerck & Company Inc (MRK)
AXSM
Axsome Therapeutics Inc
$232.32
+0.36%
HEALTHCARE · Cap: $13.13B
MRK
Merck & Company Inc
$120.79
-1.42%
HEALTHCARE · Cap: $285.64B
Smart Verdict
WallStSmart Research — data-driven comparison
Merck & Company Inc generates 9186% more annual revenue ($65.77B vs $708.24M). MRK leads profitability with a 13.6% profit margin vs -26.6%. MRK earns a higher WallStSmart Score of 50/100 (D+).
AXSM
Avoid31
out of 100
Grade: F
MRK
Hold50
out of 100
Grade: D+
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
+50.8%
Fair Value
$378.56
Current Price
$232.32
$146.24 discount
Margin of Safety
-49.3%
Fair Value
$80.88
Current Price
$120.79
$39.91 premium
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Revenue surging 57.4% year-over-year
Mega-cap, among the largest globally
Strong operational efficiency at 38.6%
Generating 2.9B in free cash flow
Areas to Watch
0.0% earnings growth
Trading at 219.2x book value
ROE of -345.0% — below average capital efficiency
Negative free cash flow — burning cash
Premium valuation, high expectations priced in
4.9% revenue growth
Elevated debt levels
Weak financial health signals
Comparative Analysis Report
WallStSmart ResearchBull Case : AXSM
The strongest argument for AXSM centers on Revenue Growth. Revenue growth of 57.4% demonstrates continued momentum.
Bull Case : MRK
The strongest argument for MRK centers on Market Cap, Operating Margin, Free Cash Flow.
Bear Case : AXSM
The primary concerns for AXSM are EPS Growth, Price/Book, Return on Equity. Debt-to-equity of 3.97 is elevated, increasing financial risk.
Bear Case : MRK
The primary concerns for MRK are P/E Ratio, Revenue Growth, Debt/Equity.
Key Dynamics to Monitor
AXSM profiles as a hypergrowth stock while MRK is a value play — different risk/reward profiles.
AXSM carries more volatility with a beta of 0.60 — expect wider price swings.
AXSM is growing revenue faster at 57.4% — sustainability is the question.
MRK generates stronger free cash flow (2.9B), providing more financial flexibility.
Bottom Line
MRK scores higher overall (50/100 vs 31/100). AXSM offers better value entry with a 50.8% margin of safety. Both earn "Hold" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Axsome Therapeutics Inc
HEALTHCARE · BIOTECHNOLOGY · USA
Axsome Therapeutics, Inc., a biopharmaceutical company, is dedicated to developing new therapies for central nervous system (CNS) disorders in the United States. The company is headquartered in New York, New York.
Visit Website →Merck & Company Inc
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
Merck & Co. is an American multinational pharmaceutical company headquartered in Kenilworth, New Jersey. It is named after the Merck family, which set up Merck Group in Germany in 1668.
Visit Website →Compare with Other BIOTECHNOLOGY Stocks
Want to dig deeper into these stocks?